RxDoctor Payments Data

Laura McMahon

Family · Pueblo, CONPI 1609008796

Payments from drug & device makers

$2,826in general payments, 2019–2025

Across 150 payments — averaging $18.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$544
  • AbbVie$444
  • AstraZeneca$430
  • Lilly USA, LLC$159
  • Pfizer$156
  • GSK$140
  • plus $953 from 20 others

What the payments were for

  • Food & beverage$2,826100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,826 in reported general payments places this provider in the 90th percentile of 2,182 family providers in Colorado.

See all family providers in Colorado

Medicare billing

Part B allowed, 2024
$22,660
Medicare patients
107
Services billed
478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$94,055
MounjaroTirzepatide49$49,222
EliquisApixaban33$30,846
CaplytaLumateperone Tosylate12$19,618
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$17,713
Tresiba Flextouch U-100Insulin Degludec36$16,947
JanuviaSitagliptin Phosphate17$16,448
OxycontinOxycodone Hcl12$15,646
FarxigaDapagliflozin Propanediol14$15,406
ShingrixVaricella-Zoster Ge/As01b/Pf29$6,575
Lantus SolostarInsulin Glargine,hum.Rec.Anlog60$5,611
ArexvyRsvpref3 Antigen/As01e/Pf13$4,148
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$3,599
Atorvastatin Calcium372$3,081
Omeprazole174$2,972

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$544$95,13369 claims
Lilly USA, LLCMounjaro$159$49,22249 claims
PfizerEliquis$156$30,84633 claims
GSKTrelegy Ellipta, Shingrix, Arexvy$140$28,43666 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$112$19,61812 claims
AstraZenecaFarxiga$430$15,40614 claims
AbbVieSynthroid$444$70915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,182 family providers in Colorado.

Other family in Pueblo

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →